Search Results - "Rothweiler, F."

Refine Results
  1. 1

    Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles by Dreis, S., Rothweiler, F., Michaelis, M., Cinatl, J., Kreuter, J., Langer, K.

    Published in International journal of pharmaceutics (16-08-2007)
    “…Human serum albumin (HSA) nanoparticles represent promising drug carrier systems. Binding of cytostatics to HSA nanoparticles may diminish their toxicity,…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status by Michaelis, M, Rothweiler, F, Loeschmann, N, Sharifi, M, Ghafourian, T, Cinatl, J

    Published in European journal of cancer (1990) (01-12-2016)
    “…Background: Enzastaurin is a PKCβ inhibitor that has been tested in clinical trials. Here, enzastaurin was tested in neuroblastoma and rhabdomyosarcoma cell…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Flubendazole as potential anti-neuroblastoma therapy option by Michaelis, M, Agha, B, Rothweiler, F, Loeschmann, N, Voges, Y, Westermann, F, Wass, M, Cinatl, J

    Published in European journal of cancer (1990) (01-12-2016)
    “…An abstract of a study by Michaelis et al on flubendazole as potential anti-neuroblastoma therapy option is presented. The study tested flubendazole for…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Substrate-specific effects of pirinixic acid derivatives on ABCB1-mediated drug transport by Michaelis, M, Rothweiler, F, Wurglics, M, Aniceto, N, Dittrich, M, Zettl, H, Wass, M, Ghafourian, T, Schubert-Zsilavecz, M, Cinatl, J

    Published in European journal of cancer (1990) (01-12-2016)
    “…Background: Pirinixic acid derivatives, a new class of drug candidates for a range of diseases, interfere with targets including PPARu, PPARy, 5-lipoxygenase…”
    Get full text
    Journal Article
  8. 8
  9. 9

    Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents by Michaelis, M, Rothweiler, F, Agha, B, Barth, S, Voges, Y, Löschmann, N, von Deimling, A, Breitling, R, Wilhelm Doerr, H, Rödel, F, Speidel, D, Cinatl, J

    Published in Cell death & disease (01-04-2012)
    “…Adaptation of wild-type p53 expressing UKF-NB-3 cancer cells to the murine double minute 2 inhibitor nutlin-3 causes de novo p53 mutations at high frequency…”
    Get full text
    Journal Article
  10. 10

    Correlation from undiluted vitreous cytokines of untreated central retinal vein occlusion with spectral domain optical coherence tomography by Koss, Mj, Pfister, M, Rothweiler, F, Rejdak, R, Ribeiro, R, Cinatl, J, Schubert, R, Kohnen, T, Koch, Fh

    Published in The open ophthalmology journal (01-01-2013)
    “…To correlate inflammatory and proangiogenic key cytokines from undiluted vitreous of treatment-naïve central retinal vein occlusion (CRVO) patients with SD-OCT…”
    Get full text
    Journal Article
  11. 11
  12. 12

    Selection of a highly invasive neuroblastoma cell population through long-term human cytomegalovirus infection by Michaelis, M, Barth, S, Breitling, R, Bruch, J, Steinberger, D, Rothweiler, F, Hackmann, K, Schröck, E, Doerr, H W, Griffin, D K, Cinatl, J, Cinatl, J

    Published in Oncogenesis (New York, NY) (01-04-2012)
    “…The human cytomegalovirus (HCMV) is suspected to increase tumour malignancy by infection of cancer and/or stroma cells (oncomodulation). So far, oncomodulatory…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19

    Cytokine determination from vitreous samples in retinal vascular diseases by Pfister, M, Koch, F H, Cinatl, J, Rothweiler, F, Schubert, R, Singh, P, Ackermann, H, Koss, M J

    “…The aim of this study was to determine cytokine levels from vitreous samples of treatment-naive patients with diabetic retinopathy (DRP), retinal vein…”
    Get full text
    Journal Article
  20. 20